Because the mice transplanted the CD106-negative mononuclear cells obtained from both nondiabetic and diabetic mice were alive, we thought that the elimination of CD106-positive fraction from the diabetic hematopoietic stem cells is the novel strategy for the treatment of diabetic neuropathy. Here, VCAM1 is linked to diabetic neuropathy.